^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Keytruda (pembrolizumab)

    i
    Other names: MK-3475, SCH 900475, 1374853-91-4, ORG 307488, SCH-900475, SCH900475, ORG 307488-0, MK 3475, MK3475
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    15h
    A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) (clinicaltrials.gov)
    P3, N=750, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • pumitamig (BNT327)
    17h
    KEYNOTE-F49: A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, ImmunOs Therapeutics AG | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Jul 2026 | Trial primary completion date: May 2025 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
    |
    Keytruda (pembrolizumab) • IOS-1002
    20h
    STU-2021-1043: Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer (clinicaltrials.gov)
    P2, N=51, Active, not recruiting, University of Texas Southwestern Medical Center | N=80 --> 51 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Checkpoint inhibition
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    22h
    INTerpath-007: A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (clinicaltrials.gov)
    P2/3, N=46, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)
    22h
    Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC (clinicaltrials.gov)
    P2, N=32, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)
    1d
    Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial. (PubMed, Nat Commun)
    We report a population of high FOLR1-expressing tumor-associated macrophages (CD163 + FOLR1 + ), suggesting potential on-target, off-tumor immune editing by MIRV. A composite biomarker score derived in this cohort correlates with objective response to MIRV and pembrolizumab.
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    FOLR1 ( Folate receptor alpha ) • CD163 (CD163 Molecule)
    |
    FOLR1 expression • FOLR1 positive
    |
    Keytruda (pembrolizumab) • Elahere (mirvetuximab soravtansine-gynx)
    3d
    Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. (PubMed, Nat Med)
    These data suggest that a subset of HRD PC may derive prolonged benefit from PARP-ICB maintenance and support further development of biomarker-guided precision immunotherapy strategies in PC. ClinicalTrials.gov identifier: NCT04666740 .
    P2 data • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • PALB2 (Partner and localizer of BRCA2)
    |
    BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    3d
    A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial Cancer. (PubMed, Clin Cancer Res)
    The combination of olaparib plus pembrolizumab has promising activity with durable responses in patients with persistent or recurrent CN-H/p53-abnormal endometrial cancer. Molecular biomarkers may be helpful for patient selection in future studies of this combination.
    P2 data • Journal • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • HRD (Homologous Recombination Deficiency) • POLE (DNA Polymerase Epsilon)
    |
    TP53 mutation • POLE mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    3d
    NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | N=30 --> 10 | Trial primary completion date: Dec 2026 --> Dec 2027
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Mobista (CDX-301) • Neo Vax (NEO-PV-01)
    3d
    FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=90, Active, not recruiting, Erasca, Inc. | N=200 --> 90 | Trial completion date: Feb 2026 --> Jun 2026 | Trial primary completion date: Nov 2025 --> Feb 2026
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • ERAS-601
    3d
    TRAP-BTCnEfficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer (2023-505722-33-00)
    P1/2, N=24, Active, not recruiting, Institut fuer Klinische Krebsforschung IKF GmbH | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • gemcitabine